Extremely low viral reservoir in treated chronically HIV-1-infected individuals.
HIV latency
HIV reservoir
HIV-specific antibodies
immunophenotyping
total HIV-DNA
Journal
EBioMedicine
ISSN: 2352-3964
Titre abrégé: EBioMedicine
Pays: Netherlands
ID NLM: 101647039
Informations de publication
Date de publication:
Jul 2020
Jul 2020
Historique:
received:
04
03
2020
revised:
20
05
2020
accepted:
26
05
2020
pubmed:
25
6
2020
medline:
26
5
2021
entrez:
25
6
2020
Statut:
ppublish
Résumé
Small viral reservoirs are found predominantly in HIV-1 controllers and individuals treated during acute/early HIV-1 infection. However, other HIV We screened 451 HIV-1-infected treated-individuals with suppressed plasma viremia for at least 3 years and stored cryopreserved peripheral blood mononuclear cells (PBMCs). Total HIV-DNA was analysed in PBMCs with ddPCR. Individuals with <50 HIV-DNA copies/10 We found that 9.3% of the individuals screened had <50 HIV-DNA copies/10 Treated chronically HIV-1-infected LoViReT represent a new phenotype of individuals characterized by an intrinsically reduced viral reservoir, less impaired CD8 MSD Spain.
Sections du résumé
BACKGROUND
BACKGROUND
Small viral reservoirs are found predominantly in HIV-1 controllers and individuals treated during acute/early HIV-1 infection. However, other HIV
METHODS
METHODS
We screened 451 HIV-1-infected treated-individuals with suppressed plasma viremia for at least 3 years and stored cryopreserved peripheral blood mononuclear cells (PBMCs). Total HIV-DNA was analysed in PBMCs with ddPCR. Individuals with <50 HIV-DNA copies/10
FINDINGS
RESULTS
We found that 9.3% of the individuals screened had <50 HIV-DNA copies/10
INTERPRETATION
CONCLUSIONS
Treated chronically HIV-1-infected LoViReT represent a new phenotype of individuals characterized by an intrinsically reduced viral reservoir, less impaired CD8
FUNDING
BACKGROUND
MSD Spain.
Identifiants
pubmed: 32580136
pii: S2352-3964(20)30205-X
doi: 10.1016/j.ebiom.2020.102830
pmc: PMC7317241
pii:
doi:
Substances chimiques
Anti-HIV Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
102830Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2020 The Authors. Published by Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest B.C. declares that outside the submitted work has received grants from Gilead, ViiV Healthcare and MSD; received consultancy fees from MSD; and a shareholder of AlbaJuna Therapeutics and AELIX therapeutics. M.G-C. declares educational/consultancy fees from BMS, Pierre Fabre, Roche, Takeda, and AstraZeneca outside the submitted work. A.S-C has received research grants from MSDAVENIR and personal fees from MSD, ViiV healthcare and Janssen, outside the submitted work. J.B. is the founder and CEO and a shareholder of AlbaJuna Therapeutics and receives grants from MSD and Grifols outside the submitted work. J.M-P. holds an institutional grant and has received educational/consultancy fees from Merck; outside the submitted work, he has received fees from AbiVax, AstraZeneca, Gilead Sciences, Grifols, Janssen, and ViiV Healthcare. All the other authors declare no competing interests.
Références
J Acquir Immune Defic Syndr. 2012 Dec 1;61(4):407-16
pubmed: 22902723
AIDS. 2015 Aug 24;29(13):1665-71
pubmed: 26372277
AIDS. 2004 Jan 2;18(1):45-9
pubmed: 15090828
Nat Protoc. 2010 Jun;5(6):1033-41
pubmed: 20539279
J Clin Virol. 2012 Jan;53(1):29-32
pubmed: 22019250
Clin Infect Dis. 2015 Jun 1;60(11):1715-21
pubmed: 25737374
PLoS Pathog. 2011 Feb;7(2):e1001300
pubmed: 21383972
Nat Med. 2003 Jun;9(6):727-8
pubmed: 12754504
J Antimicrob Chemother. 2014 Mar;69(3):753-6
pubmed: 24187041
J Acquir Immune Defic Syndr. 2018 Jun 1;78(2):239-247
pubmed: 29481485
PLoS Pathog. 2013 Mar;9(3):e1003211
pubmed: 23516360
J Infect Dis. 2017 Jul 1;216(1):72-81
pubmed: 28498985
Nature. 2019 Feb;566(7742):120-125
pubmed: 30700913
J Int AIDS Soc. 2020 Feb;23(2):e25453
pubmed: 32107887
J Clin Microbiol. 2012 Dec;50(12):3968-76
pubmed: 23035182
N Engl J Med. 2009 Feb 12;360(7):692-8
pubmed: 19213682
Lancet. 2013 Jun 15;381(9883):2109-17
pubmed: 23541541
J Infect Dis. 2008 Feb 1;197(3):411-9
pubmed: 18248304
J Immunol. 2016 Jul 15;197(2):407-17
pubmed: 27382129
J Virol. 2014 Sep 1;88(17):10056-65
pubmed: 24965451
PLoS One. 2017 Apr 17;12(4):e0175899
pubmed: 28414780
Nature. 2014 Aug 7;512(7512):74-7
pubmed: 25042999
Contemp Clin Trials. 2016 Mar;47:85-92
pubmed: 26706666
J Immunol. 2013 Sep 1;191(5):2194-204
pubmed: 23918986
J Infect Dis. 2017 Mar 15;215(suppl_3):S109-S110
pubmed: 28520965
J Infect Dis. 2005 May 1;191(9):1410-8
pubmed: 15809898
AIDS. 2016 Mar 13;30(5):761-9
pubmed: 26730568
J Antimicrob Chemother. 2019 Jul 1;74(7):2039-2046
pubmed: 31225610
J Acquir Immune Defic Syndr. 2010 Feb;53(2):167-75
pubmed: 19996764
Front Immunol. 2017 Feb 10;8:54
pubmed: 28239376
AIDS. 2000 Sep 8;14(13):1921-33
pubmed: 10997396
Nat Med. 1999 May;5(5):512-7
pubmed: 10229227
Proc Natl Acad Sci U S A. 2007 Apr 17;104(16):6776-81
pubmed: 17428922
J Clin Virol. 2008 Aug;42(4):399-404
pubmed: 18455956
J Clin Microbiol. 2012 Feb;50(2):258-63
pubmed: 22135262
Nature. 2019 Apr;568(7751):244-248
pubmed: 30836379
Elife. 2014 Sep 12;3:e03821
pubmed: 25217531
Clin Microbiol Rev. 2016 Oct;29(4):859-80
pubmed: 27559075
AIDS. 2000 Sep 8;14(13):1887-97
pubmed: 10997391
Nat Med. 2018 Jul;24(7):923-926
pubmed: 29892063
Nat Rev Immunol. 2012 Jul 20;12(8):607-14
pubmed: 22814509
Clin Microbiol Infect. 2015 Mar;21(3):288.e5-7
pubmed: 25658542
Clin Infect Dis. 2006 Mar 1;42(5):709-15
pubmed: 16447119
Lancet HIV. 2015 Jun;2(6):e236-42
pubmed: 26423196
Ann Intern Med. 2018 Nov 20;169(10):674-683
pubmed: 30326031
AIDS. 2009 Oct 23;23(16):2165-71
pubmed: 19657270
Science. 2009 Mar 6;323(5919):1304-7
pubmed: 19265012